Working… Menu

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03863184
Recruitment Status : Recruiting
First Posted : March 5, 2019
Last Update Posted : October 15, 2019
Celgene Corporation
Information provided by (Responsible Party):
Weill Medical College of Cornell University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 1, 2022
Estimated Study Completion Date : November 1, 2024